Stopping empiric antibiotics early nearly tripled antibiotic-free days in neutropenic fever, and 5-day oseltamivir prophylaxis matched 10 days in hospital exposures.
|Videos|May 14, 2017
Cost-Effective Strategies to Control Clostridium difficile in the Hospital Setting
Author(s)Contagion Editorial Staff
Gonzalo Bearman, MD, MPH, professor of medicine, and hospital epidemiologist, Department of Internal Medicine and Infectious Diseases, Virginia Commonwealth University, discusses a cost-effective way to control Clostridium difficile in the hospital setting.
Advertisement
Gonzalo Bearman, MD, MPH, professor of medicine, and hospital epidemiologist, Department of Internal Medicine and Infectious Diseases, Virginia Commonwealth University, discusses a cost-effective way to control Clostridium difficile in the hospital setting.
Interview Transcript (slightly modified for readability)
“The economic assessment of controlling C. difficile kind of falls more in favor of using what’s called the bundled approach.
So, the bundled approach would be washing your hands, isolating the patients, detecting it as quickly and as feasibly as possible, doing proper disinfection or heightened disinfection throughout hospitalization, particularly at the end of hospitalization. When those are bundled together, and there was recently a paper that looked at this, it’s probably cost-effective to use that strategy for controlling C. difficile. It doesn’t take into account using new technologies, such as UVC robots, which are expensive.”
Advertisement
Related to this article
In an ECOSPOR III analysis, all-cause hospitalization by week 4 fell to 3.4% with fecal microbiota spores vs 16.1% with placebo in recurrent C difficile infection.
Karen B. Jacobson, MD, MPH, of Kaiser Permanente Northern California, presented data at IDWeek 2026 showing 58.2% of children younger than five years exposed to active hepatitis B in the home were exposed by someone other than their birth mother, a risk maternal screening alone would miss under the CDC’s revised birth dose recommendation.
In this first IDWeek 2026 roundup, oral olorofim matched AmBisome in invasive aspergillosis, aztreonam-avibactam held activity as MBL-producing CRE rose, pritelivir cut hospitalizations in refractory HSV, and zelicapavir shortened RSV symptoms in high-risk adults.
David Altarac, MD, discusses the 2026 IDSA guidance, which prioritizes sulbactam-durlobactam plus a carbapenem for invasive carbapenem-resistant Acinetobacter infections.
Investigational agent Zelicapavir cut time to complete RSV symptom resolution by up to a week and lowered hospitalization in high-risk adults.
Preliminary SABEDTIO data from IDWeek 2026 show early dual IV therapy cut prolonged S aureus bacteremia to 6% from 16%, with safe oral transition at 72 hours.
Alejandra Gurtman, MD, discussed the phase 2 data at IDWeek 2026 which showed the investigational 25-valent pneumococcal conjugate vaccine 25vPnC produced serotype 3 antibody levels about 15-fold higher than Prevnar 20 after the booster dose, targeting a serotype still behind 10.6% of invasive pneumococcal disease in US children younger than five years.
Advertisement
Advertisement
Trending on Contagion Live
1
Early Dual Therapy Shortens Staphylococcus aureus Bacteremia in SABEDTIO Trial
2
Ebola Update: DRC Outbreak Reaches 9735 Cases, Second Largest on Record
3
IDSA 2026 Guidance Makes Sulbactam-Durlobactam the Priority for CRAB Infections
4
Novel RSV Therapy: Addressing a Clinical Need
5